FindTrial
Sign In

Studying how well adding an h2 blocker works with an h1 blocker in treating chronic spontaneous urticaria

Evaluation of efficacy of h2 blocker as an add on therapy with h1 blocker in chronic spontaneous urticaria patients an open label randomised controlled trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096178
Enrollment
200
Registered
2025-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: Tab levocetirizine 5mg and tab famotidine 40 mg: Tab levocetirizine 5mg and tab famotidine 40 mg once daily for 14 days Control Intervention1: Tab levocetirizine 5mg: Tab levocetirizine

Sponsors

Nabanita Das
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the chronic spontaneous urticaria patients diagnosed, attending dermatology opd of a tertiary care hospital in the age group between 18 years and 70 years, recurrent attacks despite standard doses of h1 antihistamines shall be included in the study

Exclusion criteria

Exclusion criteria: Known hypersensitivity to h2 blockers, use of h2 blockers within the past four weeks, patients with other significant dermatological conditions, pregnancy or breastfeeding, patient not willing to participate

Design outcomes

Primary

MeasureTime frame
Urticaria activity score, urticaria control test, percentage of participants who had reduction of urticaria activity score more than 75 percentTimepoint: day 8, day 29—

Secondary

MeasureTime frame
Dermatology life quality index , serum IgE levelTimepoint: Day 8, day 29—

Countries

India

Contacts

Public ContactDebasis Ray

Agartala government medical college and gbp hospital

contactdebasisray@gmail.com9436125100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026